Calithera Biosciences, Inc. /
Millennium Pharmaceuticals, Inc.
Calithera Biosciences amended asset purchase agreement with Millennium Pharmaceuticals
- Terms
- Not stated
- Stage
- Agreement signed
What happened
Calithera Biosciences, Inc. and Millennium Pharmaceuticals, Inc. amended the agreement covering technology, intellectual property and other assets related to Takeda’s small molecule programs TAK-228 and TAK-659.
The May 23, 2022 amendment changed the amount of certain deductibles under the agreement.
The source
Everything on this page comes from the source below.
Calithera Biosciences amended asset purchase agreement with Millennium Pharmaceuticals
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Also stated
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly